<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJOHNS</journal-id><journal-title-group><journal-title>International Journal of Otolaryngology and Head &amp; Neck Surgery</journal-title></journal-title-group><issn pub-type="epub">2168-5452</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijohns.2020.91003</article-id><article-id pub-id-type="publisher-id">IJOHNS-97161</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Recurrent Sinonasal Hemangiopericytoma: A Rare Case Report
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Worood</surname><given-names>Husain</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mahran</surname><given-names>Kazerooni</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ahmed</surname><given-names>Jamal</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of ENT, Head and Neck Surgery, Salmaniya Medical Complex, Manama, Kingdom of Bahrain</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>11</month><year>2019</year></pub-date><volume>09</volume><issue>01</issue><fpage>14</fpage><lpage>18</lpage><history><date date-type="received"><day>10,</day>	<month>November</month>	<year>2019</year></date><date date-type="rev-recd"><day>14,</day>	<month>December</month>	<year>2019</year>	</date><date date-type="accepted"><day>17,</day>	<month>December</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Hemangiopericytoma (HPC) is a rare vascular tumor arising from capillary pericytes. This tumor represents 3% - 5% of all soft tissue sarcomas and 1% of all vascular tumors. Only 15% - 30% of cases occur in the head and neck region, among which sinonasal hemangiopericytoma (HPC) is accounted for around 5% of cases. Hemangiopericytoma (HPC) has a tendency for recurrence. Here, a case of recurrent nasal hemangiopericytoma (HPC) after 12 years of treatment is reported.
 
</p></abstract><kwd-group><kwd>Hemangiopericytoma</kwd><kwd> Sinonasal Hemangiopericytoma</kwd><kwd> Endoscopic Approach</kwd><kwd> Staghorn Pattern</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Hemangiopericytoma (HPC) is a rare vascular tumor arising from capillary pericytes [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>]. Hemangiopericytoma (HPC) was first described by Stout and Murray in 1942 [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.97161-ref6">6</xref>]. It affects mainly middle-age adults but can affect all age groups with an equal sex distribution [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>]. These tumors represent 3% - 5% of all soft tissue sarcomas and 1% of all vascular tumors [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref4">4</xref>]. It tends to occur in all body parts [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>] but only 15% - 30% of cases occur in the head and neck area [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>]. Sinonasal hemangiopericytoma (HPC) is accounted for around 5% of cases [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>]. Symptoms of sinonasal HPC are nasal bleeding and obstruction. Local swelling, headache and visual symptoms suggest orbital, intracranial and cranial nerve involvement [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>]. Because these lesions tend to recur despite treatment [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>], any new symptoms in a patient diagnosed previously with sinonasal HPC should be taken into consideration [<xref ref-type="bibr" rid="scirp.97161-ref6">6</xref>].</p></sec><sec id="s2"><title>2. Case Report</title><p>A 66-year-old male who is a known case of nasal hemangiopericytoma that was excised 12 years ago, and who missed regular follow-ups, presented with unilateral nasal bleeding for a couple of weeks. The bleeding was on the right side which was the previously operated side. Nasal examination showed a tan-colored swelling in the middle part of nasal septum (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Paranasal sinuses CT scan was ordered. It showed a small well-defined mass in the right side of nasal septum around 1 &#215; 1 cm, not extending into other regions of nasal cavity or paranasal sinuses (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The lesion was completely excised by endoscopic surgery. Pathological examination of the lesion showed spindle cells surrounding dilated vessels suggestive of hemangiopericytoma. The patient was followed up for 1 year after the surgery and no recurrence was found. Given the nature of his tumor and its tendency to recur, he was advised for a lifelong follow-up.</p></sec><sec id="s3"><title>3. Discussion</title><p>Hemangiopericytoma ( HPC ) is a rare vascular tumor arising from capillary pericytes [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>]. These pericytes are modified smooth muscle cells surrounding capillaries and post-capillary venules [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>]. It represents 3% - 5% of all soft tissue sarcomas and 1% of all vascular tumors [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref4">4</xref>]. HPC affects mainly middle-age adults but can arise in all age groups with an equal sex distribution [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>]. The etiology remains largely unknown but trauma, previous steroid treatment, pregnancy and hypertension, are factors thought to be associated with the development of HPC by some [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>]. Sinonasal HPC is extremely rare and it is accounted for around 5% of cases [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>]. It tends to occur twice as common in the nasal cavity as in the paranasal sinuses [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>]. Sinonasal HPC behaves less aggressively than HPC arising from other body parts [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>], however its behavior is unpredictable and it has both benign and malignant variants [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] - [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>]. It has a tendency for local recurrence of around 25% [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>]. In some studies the local recurrence ranges from 8% to 53% [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>]. Local recurrence can be related to inadequate surgical resection particularly if occurring within one year of surgical resection [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>]. Recurrence may arise decades later [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>], which warrant a long-term follow-up [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>]. Cheng et al. recommended working up for recurrence, any patient with a history of treated HPC that develops new symptoms regardless of the length of disease free survival [<xref ref-type="bibr" rid="scirp.97161-ref6">6</xref>].</p><p>Metastasis is less common [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>] and maybe proceeded by multiple recurrences [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>]. The commonest metastasis is to the lungs [<xref ref-type="bibr" rid="scirp.97161-ref4">4</xref>].</p><p>Clinically, symptoms are mainly of nasal bleeding and obstruction. Local swelling, headache and visual symptoms suggest orbital, intracranial and cranial nerve involvement [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>]. On examination sinonasal HPC appears as a unilateral nasal mass, which could be firm, rubbery or soft with or without redness and can be as small as 1cm or as large as 20 cm [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>].</p><p>Radiological imaging of paranasal sinuses can show the lesion. It appears as a unilateral soft tissue density that enhances with intravenous contrast on CT scan [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>]. MRI would show an isointense lesion on T1and an iso- or hypo-intense lesion on T2 that enhances with gadolinium [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>].</p><p>Histopathology is the main stay diagnostic method [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] with the aid of immunohistochemical staining. Histologically, these tumors show tightly packed spindle-shaped cells with little stroma, surrounding dilated vascular channels, forming a characteristic staghorn pattern [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>]. Immunohistochemical staining are usually required to assist in the diagnosis [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>] particularly reticulin stain [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref4">4</xref>].</p><p>Sinonasal HPC is largely treated by complete surgical resection with a wide margin [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>]. Negative margins are usually difficult to achieve in the sinonasal area especially for large tumors [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>]. Small-sized sinonasal HPC can be removed efficiently by endoscopic approach [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>]. Endoscopic resection is currently the best approach, as endoscopy would avoid external scaring and localize the tumor more precisely. It would preserve the physiology of the nasal mucosa better than external approach, with the advantage of less blood loss and less chance of damaging the nasolacrimal system [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>]. Large tumors tend to require open surgery and may require preoperative angiographic embolization to decrease the chance of excessive intraoperative bleeding [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>]. For unclear margins and recurrent tumors, radiotherapy is advocated by some [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>], though sinonasal HPC is generally considered radioresistant [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>]. Chemotherapy is usually used for metastatic HPCs [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref9">9</xref>]. The role of radiotherapy and chemotherapy alone or combined as initial treatment is not yet clear [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref8">8</xref>]. Because of the tendency of HPCs to recur years after the initial treatment, a lifelong follow up is a must [<xref ref-type="bibr" rid="scirp.97161-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.97161-ref7">7</xref>].</p></sec><sec id="s4"><title>4. Conclusion</title><p>Though sinonasal HPC is a rare condition, it should be always kept in the differential diagnosis of a sinonasal mass presenting with bleeding or nasal obstruction especially in a patient who is known to have HPC treated previously. Sinonasal HPC is a lesion with a high tendency for recurrence; hence it requires a lifelong follow up.</p></sec><sec id="s5"><title>Acknowledgements</title><p>The authors thank Dr. Sara George and Dr. Nisha Chandran from pathology department at Salmaniya Medical Complex, for their assistance in providing a histopathological diagnosis.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Informed Consent</title><p>Verbal consent was obtained from the patient for publication of this manuscript and accompanying images.</p></sec><sec id="s8"><title>Cite this paper</title><p>Husain, W., Kazerooni, M. and Jamal, A. (2020) Recurrent Sinonasal Hemangiopericytoma: A Rare Case Report. International Journal of Otolaryngology and Head &amp; Neck Surgery, 9, 14-18. https://doi.org/10.4236/ijohns.2020.91003</p></sec></body><back><ref-list><title>References</title><ref id="scirp.97161-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Palacios, E., Restrepo, S., Mastrogiovanni, L., Lorusso, G.D. and Rojas, R. (2005) Sinonasal Hemangiopericytomas: Clinicopathologic and Imaging Findings. Ear, Nose &amp; Throat Journal, 84, 99-102. https://doi.org/10.1177/014556130508400214</mixed-citation></ref><ref id="scirp.97161-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Shobha, B., Shivakumar, B., Reddy, S. and Dutta, N. (2015) Sinonasal Hemangiopericytoma: A Rare Case Report with Review of Literature. Journal of Oral &amp; Maxillofacial Pathology, 19, 107. https://doi.org/10.4103/0973-029X.157214</mixed-citation></ref><ref id="scirp.97161-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Shanmugam, R., Umapathy, V., Rajagopalan, S., Balaji, M., Srikanth, S., Dony, M. and Mathaikutty, M. (2015) Haemangiopericytoma—A Rare Sino-Nasal Mass. Otolaryngology Online Journal, 5.</mixed-citation></ref><ref id="scirp.97161-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Tauro, L.F., George, C., Kamath, A., Sundaran, S. and Gatty, R. (2013) Hemangiopericytoma of the Hand. Indian Journal of Surgical Oncology, 4, 76-79. https://doi.org/10.1007/s13193-012-0194-7</mixed-citation></ref><ref id="scirp.97161-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Manea, C., Plesa, V. and Sarafoleanu, C. (2014) Sinonasal Hemangiopericytoma: Case Report and Literature Review. Romanian Journal of Rhinology, 4.</mixed-citation></ref><ref id="scirp.97161-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, K.P., Wong, W.J., Hashim, S. and Mun, K.S. (2017) Hemangiopericytoma 11 Years Later: Delayed Recurrence of a Rare Soft Tissue Sarcoma. Journal of Thoracic Disease, 9, E752-E756. https://doi.org/10.21037/jtd.2017.08.74</mixed-citation></ref><ref id="scirp.97161-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Peyvandi, A., Naghibzadeh, B. and Roozbahany, N.A. (2010) Sinonasal Hemangiopericytoma: A Case Report. Iranian Journal of Medical Sciences, 35, 251-253.</mixed-citation></ref><ref id="scirp.97161-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X., Wang, J., Hu, W., Wang, L. and Li, Y. (2015) Combined Therapy against Recurrent and Intracranial Invasion of Sinonasal Hemangiopericytoma: A Case Report. Oncology Letters, 10, 287-290. https://doi.org/10.3892/ol.2015.3236</mixed-citation></ref><ref id="scirp.97161-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Asimakopoulos, P., Syed, M.I., Andrews, T., Syed, S. and Williams, A. (2016) Sinonasal Glomangiopericytoma: Is Anything New? Ear, Nose &amp; Throat Journal, 95, E1-E6. https://doi.org/10.1177/014556131609500202</mixed-citation></ref></ref-list></back></article>